focusIR May 2024 Investor Webinar: Blue Whale, Kavango, Taseko Mines & CQS Natural Resources. Catch up with the webinar here.

Less Ads, More Data, More Tools Register for FREE

Pin to quick picksBraveheart Inv Regulatory News (BRH)

Share Price Information for Braveheart Inv (BRH)

London Stock Exchange
Share Price is delayed by 15 minutes
Get Live Data
Share Price: 4.75
Bid: 4.00
Ask: 5.50
Change: -0.25 (-5.00%)
Spread: 1.50 (37.50%)
Open: 5.00
High: 5.00
Low: 4.75
Prev. Close: 5.00
BRH Live PriceLast checked at -

Watchlists are a member only feature

Login to your account

Alerts are a premium feature

Login to your account

Further investment in Conjunct

20 Dec 2011 07:00

RNS Number : 2706U
Braveheart Investment Group plc
20 December 2011
 



20 December 2011

 

 

 

Braveheart Investment Group plc

 

Further investment in Conjunct Limited

 

 

Braveheart Investment Group (AIM: BRH) ('Braveheart' or the 'Group'), the AIM-listed specialist in growth capital investments for business angels, high net worth individuals and family offices, announces that it has led a third round of funding for its portfolio company Conjunct Limited. Investors in the c£340,000 round included the Group, Braveheart clients and Scottish Investment Bank's Scottish Co-investment Fund.

 

With the growth of the internet and an unprecedented demand for faster data transfer, fibre optic cabling is becoming mainstream, replacing traditional copper cables. To achieve faster connectivity within the fibre optic cable networks and support higher data rates, Conjunct has developed a highly innovative transceiver module, Fibre-Lyte. It is a novel packaging solution which can be applied to both datacoms and telecoms markets and has the potential to support data rates up to 300Gbps.

 

Conjunct, which is based in Livingston, central Scotland, has engaged with global organisations to integrate Fibre-Lyte into their product lines. The new money will be used to support Conjunct's production engineering activities for Fibre-Lyte manufacture and to complete development of a new Fibre-Lyte variant.

 

Geoffrey Thomson, Chief Executive of Braveheart, said: "Conjunct is now well placed to take advantage of the high demand for innovative optoelectronic solutions such as Fibre-Lyte and Conjunct is now in advanced discussions with the leading market players in optical systems."

 

Ken Allstaff, CEO of Conjunct, commented: "We are keen to move to the next stage of the Company's growth and are delighted to have again secured backing from Braveheart to allow us to offer Fibre-Lyte at costs and quantities which will enable continued market traction."

 

For further information please visit www.braveheartinvestmentgroup.co.uk and www.conjunct.co.uk or contact:

 

Braveheart Investment Group

Conjunct Limited

Geoffrey Thomson, Chief Executive

Ken Allstaff, Chief Executive

Tel: 01738 587555

Tel: 01506 465700

gthomson@braveheart-ventures.co.uk

ken.allstaff@conjunct.co.uk

 

 

Seymour Pierce Limited

Allerton Communications (for Braveheart)

Freddy Crossley (Nominated Adviser)

Peter Curtain

Paul Jewell / David Banks (Corporate broking)

Tel: 020 3137 2500

Tel: 020 7107 8000

peter.curtain@allertoncomms.co.uk

 

Notes to Editors

Braveheart Investment Group makes and manages investments in young, emerging British companies, specialising in building tax efficient portfolios for business angels, high net worth individuals and family offices. Braveheart was founded in 1997 by a small group of investors to encourage and syndicate investments in privately held companies that offered opportunities for significant growth. Fourteen years on, Braveheart is a public company with a demonstrable track record in technology investing, an established client base and various funds under management. The Group has offices in Perth, London, Yorkshire and Jersey with franchise operations in Dubai and Manchester.

 

Investments are made in unlisted companies where there is potential for significant growth through successful commercialisation of IP. Through close relationships with leading universities and innovation centres, Braveheart has access to a wide variety of emerging commercial opportunities at early stages. There are currently some 45 companies in Braveheart's diverse portfolio (includes all companies where the Group has a financial interest) and it has completed more than 90 deals.

 

Following the 2010 acquisition of Envestors Limited, the London based specialist corporate finance advisory business, Braveheart offers a unique and comprehensive suite of tax efficient products to high net worth investors.

 

This information is provided by RNS
The company news service from the London Stock Exchange
 
END
 
 
MSCTLBFTMBMBBAB
Date   Source Headline
2nd Jun 20204:36 pmRNSPrice Monitoring Extension
2nd Jun 20207:00 amRNSOperational update on Kirkstall Limited
1st Jun 20207:00 amRNSFurther re Paraytec Limited
29th May 20205:00 pmRNSTotal Voting Rights
21st May 20207:00 amRNSHolding in Phasefocus increased and other matters
20th May 20202:05 pmRNSSecond Price Monitoring Extn
20th May 20202:00 pmRNSPrice Monitoring Extension
20th May 202011:05 amRNSSecond Price Monitoring Extn
20th May 202011:00 amRNSPrice Monitoring Extension
20th May 20209:34 amRNSHolding(s) in Company
19th May 202012:48 pmRNSHolding(s) in Company
11th May 20208:51 amRNSHolding(s) in Company
11th May 20207:01 amRNSHolding(s) in Company
11th May 20207:00 amRNSHolding(s) in Company
7th May 20206:15 pmRNSHolding(s) in Company
6th May 20207:00 amRNSUpdate in response to social media speculation
4th May 20204:41 pmRNSSecond Price Monitoring Extn
4th May 20204:36 pmRNSPrice Monitoring Extension
4th May 20207:00 amRNSFurther re Kirkstall Limited
1st May 20207:00 amRNSFurther Placing to raise £350,000
29th Apr 20204:40 pmRNSSecond Price Monitoring Extn
29th Apr 20204:36 pmRNSPrice Monitoring Extension
29th Apr 20207:00 amRNSPlacing to raise £275,000
27th Apr 202011:05 amRNSSecond Price Monitoring Extn
27th Apr 202011:00 amRNSPrice Monitoring Extension
23rd Apr 20207:00 amRNSOperational update re certain investments
14th Apr 20207:00 amRNSOperational update on the Strategic Investments
3rd Mar 20207:00 amRNSOperational Update and Strategic Investments
30th Jan 20207:00 amRNSOperational update on Strategic Investments
12th Dec 20197:00 amRNSFurther investment in Pharm 2 Farm Limited
21st Nov 20197:00 amRNSOperational update on strategic investments
31st Oct 201910:55 amRNSHalf-year Report
28th Oct 20195:12 pmRNSFurther re buying remaining shares of Paraytec
19th Sep 20197:00 amRNSResults of customer trials by Pharm2Farm Limited
18th Sep 20197:00 amRNSDiscussions to buy remaining shares of Paraytec
29th Aug 201912:20 pmRNSResult of AGM
5th Aug 20197:00 amRNSPosting of annual accounts
1st Aug 20193:27 pmRNSREPLACEMENT: Final Results
1st Aug 20197:00 amRNSFinal Results
8th Jul 20197:00 amRNSInvestment in Pharm2Farm Limited
7th Jun 20197:00 amRNSUpdate to the Market
16th Apr 20197:00 amRNSDisposal of Viking Fund Managers Limited
12th Feb 201910:25 amRNSHolding(s) in Company
31st Jan 20195:17 pmRNSHolding(s) in Company
13th Dec 20187:00 amRNSFund Management Division Update
30th Oct 20187:00 amRNSInterim Results
18th Oct 201811:28 amRNSUpdate re Reduction of Share Capital
24th Sep 20189:00 amRNSConversion of Loan Notes in Paraytec Limited
4th Sep 20187:00 amRNSFurther re. Partial Disposal of Investment
21st Aug 20187:00 amRNSPartial Disposal of Investment in Gyrometric

Due to London Stock Exchange licensing terms, we stipulate that you must be a private investor. We apologise for the inconvenience.

To access our Live RNS you must confirm you are a private investor by using the button below.

Login to your account

Don't have an account? Click here to register.

Quickpicks are a member only feature

Login to your account

Don't have an account? Click here to register.